SQL NASDAQ

Globally, SeqLL Inc. operates as a life sciences enterprise, providing specialized instrumentation and research services. The company's primary focus involves the innovation, refinement, and production of cutting-edge genetic analysis technologies. Among its key offerings is the proprietary true single molecule sequencing (tSMS) platform, which facilitates the direct sequencing of DNA and RNA at the individual molecular level. SeqLL has established collaborative agreements with a range of esteemed organizations, including Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc. Its diverse clientele encompasses academic institutions, governmental agencies, hospitals and medical centers, pharmaceutical and biotechnology companies, and various non-profit research groups. Established in 2013, the company maintains its headquarters in Billerica, Massachusetts.